PLA2G7通过JAK-STAT-PDL1轴促进膀癌的免疫逃避
Ding Peng1, Wuping Yang1, Tianyu Tang1
1Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang Province, 310003, PR China.
脂酶A2第七组 (PLA2G7) 在膀癌中升高,促进瘤生长和PD-L1表达. 向PLA2G7通过增强T细胞透和与其他疗法协同作用,提供了一种新的免疫疗法策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 针对编程细胞死亡1 (PD-1) 和编程死亡联体-1 (PD-L1) 的免疫检查点抑制剂在膀癌中显示出临床益处.
- 对当前免疫疗法的低响应率需要替代治疗策略.
研究的目的:
- 调查脂酶A2第七组 (PLA2G7) 在膀癌中的作用.
- 探索PLA2G7作为膀癌免疫治疗的潜在治疗标.
主要方法:
- 研究了PLA2G7表达及其与膀癌预后的相关性.
- 利用体外淘汰实验来评估PLA2G7对癌细胞行为和PD-L1表达的影响.
- 分析了JAK-STAT通路参与PLA2G7介导的PD-L1调节.
- 评估了与抗CTLA4疗法抑制PLA2G7的协同效应在同源性小鼠模型中.
- 确定ETS1作为PLA2G7过度表达的调节者.
主要成果:
- 在膀癌中,PLA2G7显著升高,与更差的预后相关.
- 抗击PLA2G7抑制PD-L1表达,并通过增加CD8+T细胞透抑制瘤生长.
- PLA2G7通过JAK-STAT通路促进PD-L1的表达,从而对STAT1和STAT3的酸化进行上调.
- 与抗CTLA4治疗相结合的PLA2G7抑制显示出对瘤负担和存活率的协同效应.
- ETS1被确定为膀癌细胞中PLA2G7过度表达的促进体.
结论:
- 在膀癌中,PLA2G7是PD-L1表达和瘤免疫力的关键调节者.
- 准ETS1-PLA2G7-STAT通路为膀癌提供了一个新的免疫治疗策略.
- 抑制PLA2G7可能会提高现有的免疫疗法的疗效.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
相关概念视频
The JAK-STAT Signaling Pathway
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Selectins
Cancer Cell Migration through Invadopodia
Amplifying Signals via Enzymatic Cascade
